Ontology highlight
ABSTRACT: Identification of recurrent GBM patients that may benefit from Bevacizumab and CCNU: A report from the BELOB trial by the Dutch Neurooncology Group
PROVIDER: PRJNA295398 | ENA |
REPOSITORIES: ENA
ACCESS DATA
